Mitiglinide

Mitiglinide

Clinical data
Routes of administration	oral
ATC code	A10BX (WHO)
Identifiers
IUPAC name (-)-2(S)-Benzyl-4-(cis-perhydroisoindol-2-yl)butyric acid
CAS Number	207844-01-7
PubChem CID	121891
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H25NO3
Molar mass	315.41 g/mol

WikiDoc Resources for Mitiglinide
Articles
Most recent articles on Mitiglinide Most cited articles on Mitiglinide Review articles on Mitiglinide Articles on Mitiglinide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mitiglinide Images of Mitiglinide Photos of Mitiglinide Podcasts & MP3s on Mitiglinide Videos on Mitiglinide
Evidence Based Medicine
Cochrane Collaboration on Mitiglinide Bandolier on Mitiglinide TRIP on Mitiglinide
Clinical Trials
Ongoing Trials on Mitiglinide at Clinical Trials.gov Trial results on Mitiglinide Clinical Trials on Mitiglinide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mitiglinide NICE Guidance on Mitiglinide NHS PRODIGY Guidance FDA on Mitiglinide CDC on Mitiglinide
Books
Books on Mitiglinide
News
Mitiglinide in the news Be alerted to news on Mitiglinide News trends on Mitiglinide
Commentary
Blogs on Mitiglinide
Definitions
Definitions of Mitiglinide
Patient Resources / Community
Patient resources on Mitiglinide Discussion groups on Mitiglinide Patient Handouts on Mitiglinide Directions to Hospitals Treating Mitiglinide Risk calculators and risk factors for Mitiglinide
Healthcare Provider Resources
Symptoms of Mitiglinide Causes & Risk Factors for Mitiglinide Diagnostic studies for Mitiglinide Treatment of Mitiglinide
Continuing Medical Education (CME)
CME Programs on Mitiglinide
International
Mitiglinide en Espanol Mitiglinide en Francais
Business
Mitiglinide in the Marketplace Patents on Mitiglinide
Experimental / Informatics
List of terms related to Mitiglinide

Mitiglinide (trade name Glufast®) is a drug for the treatment of type 2 diabetes.

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

External links

• Elixir Pharmaceuticals - website of the U.S. rights holder for mitiglinide.

Template:WikiDoc Sources